Get notified of page updates
Glossary on
off
Clinicaltrials.gov identifier:
NCT03884101
Study Contact Information:
For additional information, please contact: 1-888-577-8839 or [email protected]
Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer
About the Study
The purpose of this study is to compare the effectiveness of using a combination of the drug pembrolizumab (Keytruda) and the lenvatinib (Lenvima) in women with III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment.
Type of Study
This is a 2-arm, , , phase 3 study.
- The study has two arms, which means patients will be placed into one of two groups.
- Patients assigned to Group 1 will receive will receive lenvatinib and pembrolizumab
- Patients assigned to Group 2 will receive the chemotherapy drugs paclitaxeland carboplatin
- The study is . Patients will be selected by chance and placed into one of the two groups.
- The study is , all patients will know which group they have been placed into.
What the Study Entails
- Group 1 participants will take lenvatinib daily (orally) and will receive pembrolizumab intravenously once at the start of each 3-week treatment cycle.
- Group 2 participants will receive chemotherapy medications paclitaxel intravenously and carboplatin intravenously on Day 1 of each 3-week treatment cycle.
Follow up
- Progression-free survival (the length of time that a patient survives without progression of the disease) of patients in this study will be measured for up to approximately 31 months.
- Overall survival of patients will be followed for up to approximately 45 months.
Study Sites
| Alabama | Arizona | California | Colorado | Connecticut |
| Georgia | Louisiana | Maine | Minnesota | New Jersey |
| New York | North Carolina | North Dakota | Oregon | South Dakota |
| Texas | Washington |
- Mobile: University of South Alabama, Mitchell Cancer Institute
Contact: 251-445-9834
- Tucson: Arizona Oncology Associates PC- HOPE
Contact: 281-863-6507
- Los Angeles: UCLA Hematology and Oncology Clinic (Westwood)
Contact: 310-794-6982
- Aurora: University of Colorado Cancer Center
Contact: 303-724-2066
- New Haven: Smilow Cancer Hospital at Yale New Haven
Contact: 203-785-6398
- Augusta: Georgia Cancer Center at Augusta University
Contact: 706-721-4805
- Covington: Women's Cancer Care
Contact: 985-892-2252
- Scarborough: Maine Medical Partners
Contact: 207-396-8376
- Minneapolis: Minnesota Oncology Hematology, PA
Contact: 281-863-6507
- Basking Ridge: Memorial Sloan-Kettering Cancer Center At Basking Ridge
Contact: 646-888-4224 - Hackensack: John Theurer Cancer Center at Hackensack University Med Ctr
Contact: 551-996-4716 - Middletown: Memorial Sloan Kettering Cancer Center- Monmouth
Contact: 646-888-4466 - Montvale: MSKCC-Bergen
Contact: 646-888-4466 - Teaneck: Holy Name Medical Center
Contact: 201-227-6200
- Commack: Memorial Sloan-Kettering Cancer Center at Commack
Contact: 646-888-4466 - Harrison: Memorial Sloan Kettering Cancer Center - West Harrison
Contact: 646-888-4424 - New York City:The Blavatnik Family- Chelsea Medical Center at Mount Sinai
Contact: 212-604-6059 - New York City: Memorial Sloan Kettering Cancer Center
Contact: 646-888-4224 - Rochester: University of Rochester
Contact: 585-275-5345 - Uniondale: Memorial Sloan Kettering Cancer Center - Nassau
Contact: 646-888-4466
- Chapel Hill: University of North Carolina- Chapel Hill
Contact: 919-966-4432
- Fargo: Roger Maris Cancer Center
Contact: 605-312-3250
- Eugene: Willamette Valley Cancer Institute and Research Center
Contact: 281-863-6507
- Sioux Falls: Sanford Cancer Center Oncology Clinic
Contact: 605-312-3343
- Dallas: Parkland Health & Hospital System
Contact: 214-648-7097 - Dallas: University of Texas Southwestern Medical Center
Contact: 214-648-3026 - The Woodlands: Texas Oncology-The Woodlands
Contact: 281-863-6507
- Vancouver: Legacy Salmon Creek Medical Center
Contact: 503-413-8654
This Study is Open To:
NOTE: This study has completed enrollment.
This Study is Not Open To: